Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS
NCT06334094 · The University of Texas at Dallas · PHASE4 · withdrawn · last registry update 2024-08-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The funding for the study was revoked. As such, the study is no longer being conducted.” | – | Registry record, The University of Texas at Dallas |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against S1PR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-07-15Results posted on the registry: Pfizer, Etrasimod + Placebo (NCT04607837)
- 2025-06-12Also stopped (terminated): Celgene, RPC-1063 (NCT04140305)
- 2025-05-13Results posted on the registry: State University of New York at Buffalo, Mayzent + Ocrevus (NCT04925557)
- 2025-05-13Also stopped (terminated): State University of New York at Buffalo, Mayzent + Ocrevus (NCT04925557)
- 2025-05-08Results posted on the registry: Pfizer, etrasimod + Placebo (NCT05732454)
- 2025-05-08Also stopped (terminated): Pfizer, etrasimod + Placebo (NCT05732454)
- 2025-04-22Results posted on the registry: Bristol-Myers Squibb, Ozanimod (NCT05470985)
- 2025-04-22Also stopped (terminated): Bristol-Myers Squibb, Ozanimod (NCT05470985)
- 2025-03-26Also stopped (terminated): Bristol-Myers Squibb, Ozanimod + Placebo (NCT05644665)
- 2025-03-24Results posted on the registry: Pfizer, Etrasimod Immediate Release (IR) (NCT06140290)
- 2025-02-21Results posted on the registry: Actelion, Ponesimod (NCT03232073)
- 2025-02-10Results posted on the registry: Pfizer, Estraimod Immediate Release (IR) + Etrasimod Mini Tab in water (NCT05956002)
- 2025-02-04Also stopped (terminated): Actelion, Ponesimod (NCT02461134)
- 2025-01-22Results posted on the registry: Celgene, Tetanus, diphtheria, and acellular pertussis vaccine + Pneumococcal polysaccharide vaccine (NCT05028634)
- 2025-01-15Also stopped (terminated): I.R.C.C.S. Fondazione Santa Lucia, Ozanimod Oral Capsule (NCT05777902)
- 2025-01-14Results posted on the registry: Wake Forest University Health Sciences, Fingolimod + Placebo (NCT04088630)
- 2024-12-05Results posted on the registry: Celgene, Ozanimod (NCT03440385)
- 2024-10-29Results posted on the registry: Pfizer, Etrasimod + Etrasimod (NCT05061446)
- 2024-10-01Results posted on the registry: Actelion, Ponesimod 10 mg + Ponesimod 20 mg (NCT01093326)
- 2024-09-19Also stopped (withdrawn): Geert D'Haens, Ozanimod Oral Capsule (NCT06188637)
- 2024-06-26Phase 3 first posted: Viatris Innovation GmbH, Cenerimod (NCT06475742)
- 2024-06-26Results posted on the registry: Pfizer, Etrasimod + Etrasimod (NCT04556734)
- 2024-05-17Results posted on the registry: Novartis Pharmaceuticals, BAF312 + Baseline disease modifying therapies (DMTs) (NCT04792567)
- 2024-05-10Phase 3 first posted: Bristol-Myers Squibb, Ozanimod + Fingolimod (NCT06408259)
- 2024-02-20Also stopped (terminated): Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Ozanimod (NCT04405102)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision